RedHill Biopharma Ltd. (RDHL)
- Previous Close
0.4289 - Open
0.4004 - Bid 0.4118 x 200
- Ask 0.4218 x 200
- Day's Range
0.4000 - 0.4309 - 52 Week Range
0.2570 - 3.2800 - Volume
190,389 - Avg. Volume
707,903 - Market Cap (intraday)
13.381M - Beta (5Y Monthly) 3.46
- PE Ratio (TTM)
0.10 - EPS (TTM)
4.0000 - Earnings Date Jun 10, 2024 - Jun 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
760.00
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
www.redhillbio.com53
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: RDHL
Performance Overview: RDHL
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RDHL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RDHL
Valuation Measures
Market Cap
13.38M
Enterprise Value
8.98M
Trailing P/E
0.10
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.42
Price/Book (mrq)
6.47
Enterprise Value/Revenue
1.38
Enterprise Value/EBITDA
0.34
Financial Highlights
Profitability and Income Statement
Profit Margin
366.25%
Return on Assets (ttm)
-15.71%
Return on Equity (ttm)
--
Revenue (ttm)
6.53M
Net Income Avi to Common (ttm)
23.92M
Diluted EPS (ttm)
4.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.57M
Total Debt/Equity (mrq)
56.69%
Levered Free Cash Flow (ttm)
-18.23M